Heartbeam, Inc. - Common Stock (BEAT)
1.2705
+0.4605 (56.85%)
NASDAQ · Last Trade: Dec 10th, 12:05 PM EST
Detailed Quote
| Previous Close | 0.8100 |
|---|---|
| Open | 1.450 |
| Bid | 1.270 |
| Ask | 1.280 |
| Day's Range | 1.200 - 1.600 |
| 52 Week Range | 0.5400 - 3.480 |
| Volume | 197,120,359 |
| Market Cap | 43.53M |
| PE Ratio (TTM) | 2.703 |
| EPS (TTM) | 0.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 6,583,997 |
Chart
About Heartbeam, Inc. - Common Stock (BEAT)
Heartbeam Inc is a healthcare technology company focused on developing innovative solutions for cardiac care. The company specializes in advanced heart monitoring technologies, particularly through its proprietary platform that combines telemedicine with electrocardiogram (ECG) technology. Heartbeam's products aim to provide healthcare professionals and patients with real-time monitoring and analysis of heart health, facilitating early detection of potential issues and improving patient outcomes. By leveraging cutting-edge technology, Heartbeam seeks to enhance the management of cardiovascular diseases and promote more informed healthcare decisions. Read More
News & Press Releases
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
Via Chartmill · December 10, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment after successfully appealing a prior NSE determination. The patented cable-free technology captures cardiac electrical signals in three non-coplanar dimensions to generate a synthesized 12-lead ECG that can be reviewed remotely by a board-certified cardiologist, enabling patients to capture meaningful ECG data wherever symptoms occur. With clearance in hand, HeartBeam plans a limited U.S. launch in early 2026 with select cardiology groups, alongside advancing programs in heart attack detection, development of an on-demand 12-lead extended wear patch, and the creation of AI-powered screening and prediction algorithms driven by longitudinal data from its 3D ECG platform.
Via Investor Brand Network · December 10, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · December 10, 2025
Why Did BEAT Stock Rocket 72% In Pre-Market Today?stocktwits.com
Via Stocktwits · December 10, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior Not Substantially Equivalent (NSE) determination.
By HeartBeam, Inc. · Via Business Wire · December 10, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · December 1, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac-care insights, detailed its strategy following receipt of a Not Substantially Equivalent decision for its 510(k) submission covering its 12-lead ECG Synthesis Software. The Company has been in active discussions with FDA review staff, which have signaled willingness to work toward a constructive resolution. HeartBeam said its VALID-ECG clinical study met endpoints and that remaining FDA concerns may be resolved through revised labeling. To advance the process, the Company plans to pursue multiple parallel paths—including a formal appeal or a 510(k) resubmission—and believes recent interactions indicate a viable path forward under the appeal option, which carries an expected 60-day timeline. HeartBeam will continue providing updates on commercialization and funding plans as regulatory engagement progresses.
Via Investor Brand Network · December 1, 2025
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 28, 2025
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · November 28, 2025
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Via Chartmill · November 28, 2025
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via Chartmill · November 28, 2025
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · November 28, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · November 28, 2025
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · November 27, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · November 26, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following receipt of a Not Substantially Equivalent (NSE) decision on the Company’s 510(k) submission for its 12-lead Electrocardiogram (ECG) Synthesis Software.
By HeartBeam, Inc. · Via Business Wire · November 26, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · November 25, 2025
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via Chartmill · November 24, 2025
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · November 21, 2025
The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.
Via Stocktwits · November 21, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised in the Future of Cardiac Care with Breakthrough Technology
HeartBeam (NASDAQ: BEAT) is on the verge of transforming how atrial fibrillation (“AF”) is detected and managed with its cable-free ECG technology. A recent article discussing this reads, “HeartBeam has developed a credit card-sized device and proprietary synthesis software that can capture heart signals in three dimensions and convert them into a full synthesized 12-lead ECG. By bringing clinical -grade cardiac diagnostics into the hands of patients wherever they are, HeartBeam is positioning itself at the forefront of a revolution in heart health, one that could greatly impact lives, reduce costs, and redefine the future of cardiac care.”
Via Investor Brand Network · November 19, 2025
NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates
HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510(k) review with anticipated clearance by year end. The company is advancing commercial readiness, including a new partnership with HeartNexus for 24/7 cardiologist review services, alongside new scientific data presented at AHA Scientific Sessions and HRX Live 2025 and an expanded global IP portfolio of 24 issued patents. For the quarter, R&D expenses were $3.3 million, G&A expenses were $2.0 million, net loss was $5.3 million and cash totaled $1.9 million. HeartBeam will discuss its results and provide a business update during a conference call and webcast on Nov. 13 at 4:30 p.m. ET.
Via Investor Brand Network · November 14, 2025
HeartBeam reports Q3 2025 results, missing EPS estimates. The pre-revenue firm focuses on FDA clearance for its cardiac tech, a key milestone expected by year-end.
Via Chartmill · November 13, 2025
HeartBeam (BEAT) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 13, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2025.
By HeartBeam, Inc. · Via Business Wire · November 13, 2025